Alembic Pharmaceuticals reported Q4 revenue of INR1,838 crores, up 4% YoY, with EBITDA before R&D at INR455 crores and margins at 25%.
Management provided FY27 guidance targeting low double-digit consolidated growth, with R&D spend of INR750-800 crores and capex of INR300-350 crores.
The company launched Pivya through its U.S. branded subsidiary, expecting a 100-150 bps margin drag for 1-2 quarters before contribution improves.
Operational highlights include improved facility utilization, 6 new U.S. launches, and strong 20% growth in ex-U.S. markets for full year FY26.